INNOVATIVE TREATMENTS FOR CYSTIC FIBROSIS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review presents current etiological and pathogenetic methods for the personalized therapy of cystic fibrosis in relation to the class and type of mutation in the CFTR gene. It considers the first innovation agents for the treatment of cystic fibrosis and new promising developments.

全文:

受限制的访问

作者简介

Yu. Kondratyeva

Research Center for Medical Genetics, Moscow

Email: elenafpk@mail.ru
Professor, MD

参考

  1. Каширская Н.Ю., Красовский С.А., Черняк А.В. и др. Динамика продолжительности жизни больных муковисцидозом, проживающих в Москве, и ее связь с получаемой терапией (ретроспективный анализ 1993-2013 годы) // Вопр. соврем. педиат. -2015; 4: 503-5.
  2. Welsh M., Smith A. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis // Cell. - 1993; 73: 1252-4.
  3. Kerem B., Kerem E. The molecular basis for disease variability in cystic fibrosis // Eur. J. Hum. Genet. - 1996; 4: 65-73.
  4. Castellani C., Cuppens H., Macek Jr. M. et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice // J. Cyst. Fibr. - 2008; 8: 179-96.
  5. Zielenski J. Genotype and phenotype in cystic fibrosis // Respiration. - 2000; 67 (2): 117-33.
  6. Witt H. Chronic pancreatitis and cystic fibrosis // Gut. - 2003; Suppl. 2: 1131-41.
  7. Муковисцидоз. Под ред. Н.И. Капранова, Н.Ю. Каширской / М.: МЕДпрактика-М, 2014; 672 с.
  8. Сычев Д.А., Сулейманов С.Ш., Кукес В.Г. Персонализированная медицина как путь к рациональному применению лекарственных средств: предпосылки, реалии, проблемы и перспективы для отечественной системы здравоохранения // Здравоохранение Дальнего Востока. - 2010; 1: 2-7.
  9. Riordan J., Rommens J., Kerem B. et al. Identification of the cystic fibrosis gene: Cloning and the characterization of complementary DNA // Science. - 1989; 245: 1066-73.
  10. Loubieres Y., Grenet D., Simon-Bouy B. et al. Association between genetically determined pancreatic status and lung disease in adult cystic fibrosis patients // Chest. - 2002; 121 (1): 73-80.
  11. Jentsch T., Maritzen T., Zdebik A. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function // J. Clin. Invest. - 2005; 115: 2039-46.
  12. Mishra A., Greaves R., Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era // Clin. Biochem. Rev. - 2005; 26: 135-53.
  13. Kogan I., Ramjeesingh M., Li C. et al. CFTR directly mediates nucleotide-regulated glutathione flux // The EMBO J. - 2003; 22 (9): 1981-9.
  14. http://www.cfgenetherapy.org.uk/
  15. http://www.cysticfibrosis.org.uk/news/gtc-results-statement
  16. http://www.genet.sickkids.on.ca/cftr
  17. http:www.genet.sickkids.on.ca
  18. Гуськова А.А., Скоблов М.Ю., Баранова А.В. Жизнь и смерть белка CFTR // Мед. генетика. - 2007; 6 (2): 3-9.
  19. The Cystic Fibrosis Genetic Analysis Consortium: Population variation of common cystic fibrosis mutations // Hum. Mutat. - 1994; 4 (3): 167-77.
  20. Linde L., Boelz S., Nissim-Rafinia M. et al. Ninsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin // J. Clin. Invest. - 2007; 117: 1-9.
  21. Амелина Е.Л., Ашерова И.К., Волков И.К. и др. Регистр больных муковисцидозом в Российской Федерации, 2013 год // Пульмонология. - 2015; Прил.: 1-60.
  22. Sermet-Gaudilus I., Renouil M., Fajac A. et al. In vitro prediction of stop codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study // BMC Med. - 2007; 5: 5.
  23. Kerem E., Armoni S., Hirawat S. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial // Lancet. - 2008; 372: 719-27.
  24. https://clinicaltrials.gov/ct2/show/NCT02107859
  25. Van Goor F., Hadida S., Grootenhuis P. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 // Proc. Natl. Acad. Sci. USA. - 2009; 106 (44): 18825-30.
  26. http://clinicaltrials.gov (NCT00909532)
  27. Vankeerberghen A., Wei L., Jaspers M. et al. Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator // Hum. Mol. Genet. - 1998; 7: 1761-9.
  28. Rowntree R., Harris A. The phenotypic consequences of CFTR mutations // Ann. Hum. Genet. - 2003; 67: 471-85.
  29. Kerem E. Mutation specific therapy in CF // Paediatr. Respir. Rev. - 2006; 7 (1): 166-9.
  30. Proesmans M., Vermeulen F., De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect // Eur. J. Pediatr. - 2008; 167 (8): 839-49.
  31. FDA approves Kalydeco to treat rare form of cystic fibrosis (Press release). Food and Drug Administration. 31 January 2011. Retrieved 24 June 2012.
  32. Vertex Wins Approval for Kalydeco to Treat Cystic Fibrosis. Bloomberg Businessweek. Retrieved 24 June 2012.
  33. Orphan Drugs: Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding // BMJ. - 348: g1445. doi: 10.1136/bmj. g1445.
  34. Ramsey B., Davies J., McElvaney N. et al. CFTR potentiator in patients with cystic fibrosis and the G551D mutation // N. Engl. J. Med. - 2011; 365: 1663-72.
  35. Flume P., Liou T., Borowitz D. et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation // Chest. - 2012.
  36. Van Goor F., Hadida S., Grootenhuis P. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 // Proc. Natl. Acad. Sci. USA. - 2011; 108 (46): 18843-8.
  37. Cain C. Cystic fibrosis two-step // Sci. BX. - 2012; 5 (8): doi:101038/scibx2012192.
  38. Study of VX-809 alone and in combination with VX-770 in cystic fibrosis (CF) patients homozygous or heterozygous for the F508del-CFTR mutation. URL: http://clinicaltrials.gov/ct2/show/NCT01225211?term=ivacaftor&intr=ivacaftor&rank=4.
  39. Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTRmutation. URL: http://clinicaltrials.gov/ct2/show/NCT01531673term=ivacaftor&intr=ivacaftor&rank=2.
  40. http://investors.vrtx.com
  41. http://investors.vrtx.com/releasedetail.cfm
  42. Rosen Ch., Shezen E., Aronovich A. et al. Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice // Nature Medicine. - 2015; 21: 869-79.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2016